Role Of Macrophages Residing On The Bone Surface In Bone Renodelling And Repair
Funder
National Health and Medical Research Council
Funding Amount
$54,466.00
Summary
To determine if the F4-80+ macrophages that reside on the bone surface, bone lining macrophages (BLMs) are responsible for the detection of apoptotic osteocyte cells and subsequently initiate bone remodelling in response to bone damage.
Mechanisms For The Development Of Leukaemia Via Antibody Hypermutation
Funder
National Health and Medical Research Council
Funding Amount
$82,421.00
Summary
During responses to infection, the antibody genes in responding B cells mutate at a high rate, resulting in B cells producing better antibodies. Although essential for long-lived immunity, antibody mutation involves the introduction of DNA breaks which can occasionally cause leukemia or lymphoma. We understand only poorly how DNA repair systems normally make sure that antibody mutation is benign and does not cause cancer.
Further Characterisation Of The Role Of HSSB1 In DNA Repair And Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$85,526.00
Summary
To date, all breast cancer predisposition genes identified play an important role in the DNA damage repair pathway. We have characterised a new protein designated as hSSB1, which plays a crucial role in the maintenance of genomic stability by protecting us from DNA damage. Significantly, evidence strongly suggests an interaction of hSSB1 with the breast cancer susceptibility protein BRCA2. This project will investigate the role of hSSB1 in breast cancer predisposition and DNA damage repair.
Drug Resistance In DNA Repair Defective Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$122,032.00
Summary
Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and respond to new PARP inhibitor therapy, yet even then the cancer often recurs. I will use a new model to study human ovarian cancers in mice. My focus will be understanding resistance to PARP inhibitors in individual ovarian cancers and designing approaches to overcome this resistance.